Loading…

Hoya Corp7741.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties

Maker of photomask blanks/EUV optics for chipmaking and life-care products like eyeglass and contact lenses.

≈ A hybrid of a niche optics supplier (like a smaller Corning) and an eyecare companyMomentum weak 24
Mkt cap
$49.0B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$221M
20-day average traded
Fwd P/E
27.7×
forward earnings
ROIC−WACC
+33.8 pp
WACC 8.4%
Hurdle
+2 pp
Req g minus delivered
Next earnings
76 days
2 Feb 2027
Close · JPY¥23,480
1D+0.9%
1W-1.6%
1M-8.2%
3M-11.9%
6M-16.2%
YTD-0.2%
1Y-6.0%
ATR %3.4%
52w lowhigh22.8% off high

What Hoya does

Maker of photomask blanks/EUV optics for chipmaking and life-care products like eyeglass and contact lenses.

Splits into a health-care side selling eyeglass lenses and endoscopes, the latter through Pentax Medical, and an electronics side selling photomask blanks, the glass plates that chip makers turn into printing masks, plus glass substrates for hard drives. Mask blanks go to a small number of mask makers under long-qualified supply relationships.

In one line: A hybrid of a niche optics supplier (like a smaller Corning) and an eyecare company.

Products and services

  • Semiconductor photomask blanks/EUV optics
  • Eyeglass lenses
  • Contact lenses
  • Medical devices (endoscope components)

Customers

  • Photomask makers/chipmakers
  • Eyewear retailers/opticians
  • Contact-lens and medical-device buyers

Where it sits in the supply chain

  • Semiconductors + healthcare
  • Photomasks/optics + life-care
  • Mask blanks, lens materials, medical…

What could go right

  • Semiconductor advanced-node demand
  • Aging-population eyecare/medical demand

What could go wrong

  • Semiconductor cycle exposure (mask-blank segment)

Moat: wide (scale, process know-how, IP / patents). Dominant, near-monopoly share in photomask blanks, a highly specialized, hard-to-replicate manufacturing process.

Headquarters: Tokyo, Japan · Founded: 1941 · Employees: 37,752

Named competitors

Hoya at a glance

Size Hoya (7741.T) is a Japan Health Care company (Medical Specialties) with a market value of $49.0B, the 30th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥23,480 on 18 Nov 2026.

Performance Over six months the shares fell 16.2%, against +26.7% for the median peer and -1.4% for the Japan market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 13.0% over the last twelve months (peer median +8.4%); the operating margin is 31.5% (peer median 20.4%).

Valuation It trades at 27.7× forward earnings against a peer median of 27.2× (10th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 33.8 points above its cost of capital (8.4% WACC).

Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 1267741.T 85
Six months, rebased to 100: Hoya against the median of its 20 peers (local-currency closes).

Hoya financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥1.01T¥948B¥866B¥763B¥724B
Revenue growth—+9%+14%+5%—
Gross profit¥796B¥749B¥694B¥606B¥567B
EBITDA¥382B¥439B¥392B¥344B¥342B
Net income¥282B¥253B¥202B¥181B¥169B
Free cash flow¥249B¥222B¥187B¥182B¥168B
Capital expenditure¥57.3B¥56.6B¥47.9B¥41.1B¥33.5B
Total debt¥42.2B¥42.2B¥37.3B¥29.2B¥24.6B

Quarterly statements and history in the cockpit →

Hoya competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%+60%-10%0%+10%+20%AMDLNWATSHLIDXXBDXEWBSXGEHCALCMTDRMD300760ILMNDXCMWSTELSTE45437741.T6-month return →1-month return →
Up and to the right = strong over both horizons. Hoya is the large dot.

Fundamentals: revenue growth against valuation

0%+5%+10%+15%20×30×40×AMDLNWATSHLIDXXBDXEWBSXGEHCALCMTDRMD300760ILMNDXCMWSTELSTEDIM45437741.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hoya is the large dot.

Capital: growth delivered against growth the price implies

0%+10%+20%+30%0%10%20%30%AMDLNWATSHLIDXXBDXEWBSXGEHCALCMTDRMD300760ILMNDXCMWSTELSTEDIM45437741.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Hoya is the large dot.

Hoya competitors and peer comparison

Head to head with its named competitors (7741.T vs EL.PA vs 4063.T vs 5201.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Hoya 7741.T$49.0B-16%+13%32%27.7×14.1%
EssilorLuxottica EL.PA$91.9B+5%+8%12%24.8×18.4%
Shin-etsu Chemical 4063.T$67.9B-22%+5%25%17.7×9.9%
Agc 5201.T$6.30B-18%+8%5%14.5×6.5%

How Hoya compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hoya against its 20 peers (data as of 18 Nov 2026)
Measure7741.TPeer medianRank in peer set
1-month return-8.2%+7.3%2nd lowest of 21
6-month return-16.2%+26.7%2nd lowest of 21
Distance from 52-week high-22.8%-7.5%5th lowest of 21
Revenue growth (TTM)+13.0%+8.4%5th highest of 21
Operating margin31.5%20.4%3rd highest of 21
Forward P/E27.7×27.2×10th most expensive of 21
Growth the price implies (Req g, 7 yrs)14.1%16.5%10th least demanding of 21
Growth delivered (Del g)+11.6%+8.3%7th highest of 21
Hurdle (Req g minus delivered)+2.5 pp+5.0 pp9th least demanding of 21
ROIC minus cost of capital+33.8 pp+3.7 pp2nd highest of 21
EV / EBITDA19.1×20.2×10th cheapest of 20
Net debt / EBITDA-1.4×1.5×2nd least indebted of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Hoya 7741.TJapan$49.0B-16%+13%32%27.7×14.1%+11.6%
Agilent Technologies AUnited States$50.0B+56%+9%24%27.0×23.3%+5.4%
Medline MDLNUnited States$51.5B+8%+12%6%25.6×15.9%+9.9%
Waters WATUnited States$45.8B+37%+81%10%29.1×48.1%+6.0%
Siemens Healthineers SHL.DEGermany$53.7B+27%+1%14%18.9×9.6%+5.6%
Idexx Laboratories IDXXUnited States$55.0B+26%+12%32%42.9×29.0%+9.7%
Becton Dickinson BDXUnited States$58.9B+48%-7%16%16.3×-1.6%+0.3%
Edwards Lifesciences EWUnited States$60.5B+27%+13%29%32.3×17.1%+6.7%
Boston Scientific BSXUnited States$63.3B-23%+9%21%14.1×5.8%+15.2%
GE HealthCare GEHCUnited States$37.8B+30%+7%14%15.6×5.0%+3.7%
Alcon ALC.SWSwitzerland$36.9B+18%+1%12%21.5×12.2%+6.1%
Mettler Toledo MTDUnited States$34.6B+60%+7%29%33.7×20.1%+5.5%
ResMed RMDUnited States$34.1B+16%+9%34%19.7×5.7%+12.1%
Shenzhen Mindray Bio-Medical Electronics 300760.SZChina$33.6B+15%+5%28%27.3×1.0%+9.7%
Illumina ILMNUnited States$31.8B+48%+6%21%35.2×27.2%+6.0%
Dexcom DXCMUnited States$30.8B+16%+13%24%28.0×19.6%+19.3%
West Pharmaceutical Services WSTUnited States$28.1B+32%+13%23%40.2×25.8%+7.4%
EssilorLuxottica EL.PAFrance$91.9B+5%+8%12%24.8×18.4%+14.6%
Steris STEUnited States$25.2B+21%+8%20%21.9×14.0%+13.8%
Sartorius Stedim Biotech DIM.PAFrance$24.2B+32%+4%19%45.7×33.4%+9.2%
Terumo 4543.TJapan$24.0B+32%+15%17%27.8×8.8%+13.0%

Questions

Who are Hoya's main competitors?
Named competitors: EssilorLuxottica (EL.PA), Shin-Etsu Chemical (4063.T), AGC Inc (5201.T). The cockpit's measured peer set (industry) also includes Agilent Technologies (A), Medline (MDLN), Waters (WAT), Siemens Healthineers (SHL.DE), Idexx Laboratories (IDXX), Becton Dickinson (BDX).
Is Hoya expensive compared with its peers?
On forward p/e it trades at 27.7× against a peer median of 27.2×, 10th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Hoya stock performed?
Over six months to 18 Nov 2026 the shares returned -16.2% against +26.7% for the median peer; over one year -6.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.